Stephanie Wittkoetter
Primary Care · O Fallon, MONPI 1568172260
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 28.0% of the total.
Across 114 payments — averaging $18.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$592
- Novo Nordisk$347
- Lilly USA, LLC$316
- Pfizer$149
- Exact Sciences$124
- GSK$82
- plus $502 from 14 others
What the payments were for
- Food & beverage$2,112100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 33 | $592 |
| Novo Nordisk | 18 | $347 |
| Lilly USA, LLC | 15 | $316 |
| Pfizer | 9 | $149 |
| Exact Sciences | 7 | $124 |
| GSK | 5 | $82 |
| Boehringer Ingelheim | 3 | $58 |
| AstraZeneca | 4 | $58 |
| Nevro Corp. | 3 | $55 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Bayer | 2 | $40 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $38 |
| Amgen | 2 | $37 |
| Tris Pharma Inc | 2 | $36 |
| Merck | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Abbott | 1 | $22 |
| Edwards Lifesciences | 1 | $22 |
| Ironshore Pharmaceuticals Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
How this compares
$2,112 in reported general payments places this provider in the 80th percentile of 106 primary care providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $50,600 |
| FarxigaDapagliflozin Propanediol | 13 | $17,127 |
| MounjaroTirzepatide | 14 | $14,669 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $5,678 |
| Gabapentin | 38 | $776 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $585 |
| Atorvastatin Calcium | 84 | $516 |
| Levothyroxine Sodium | 45 | $463 |
| Tamsulosin Hcl | 22 | $458 |
| Metformin Hcl ErMetformin Hcl | 28 | $444 |
| Duloxetine Hcl | 18 | $415 |
| Mirtazapine | 13 | $387 |
| Lisinopril | 64 | $356 |
| Amlodipine Besylate | 61 | $355 |
| Trazodone Hcl | 42 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $347 | $50,60028 claims |
| AstraZenecaFarxiga | $58 | $17,12713 claims |
| Lilly USA, LLCMounjaro | $316 | $14,66914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 primary care providers in Missouri.
Other primary care in O Fallon
- Jessica FooteO Fallon$2K
- Danielle ToalCape Girardeau$15K
- Joy MurphySaint Louis$7K
- Katrina SelsorSparta$6K
- Kelly EspositoSaint Louis$6K
- Elizabeth YoungSaint Louis$5K
- Carol HarringtonIndependence$4K
- Melanie HenryHayti$4K
- Heather BealSaint Louis$4K
- Taylor HeathSparta$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.